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Abstract
Objective: economic evaluation is a fundamental criterion 
when deciding a drug’s place in therapy. The MADRE method 
(Method for Assistance in making Decisions and Writing Drug 
Evaluation Reports) is widely used for drug evaluation. This 
method was developed by the GENESIS group of the Spanish 
Society of Hospital Pharmacy (SEFH), including economic eva-
luation. We intend to improve the economic aspects of this 
method. As for the direction to take, we have to first analyze 
our previous experiences with the current methodology and 
propose necessary improvements.
Method: economic evaluation sections in collaboratively con-
ducted drug evaluation reports (as the scientific society, SEFH) 
with the MADRE method were reviewed retrospectively.
Results: thirty-two reports were reviewed, 87.5% of them 
included an economic evaluation conducted by authors and 
65.6% contained published economic evaluations. In 90.6% 
of the reports, a Budget impact analysis was conducted. The 
cost per life year gained or per Quality Adjusted Life Year gai-
ned was present in 14 reports. Twenty-three reports received 
public comments regarding the need to improve the economic 
aspect. Main difficulties: low quality evidence in the target po-
pulation, no comparative studies with a relevant comparator, 
non-final outcomes evaluated, no quality of life data, no fixed 
drug price available, dosing uncertainty, and different prices 
for the same drug.
Conclusions: proposed improvements: incorporating different 
forms of aid for non-drug costs, survival estimation and adap-
Evaluación económica en los informes de medicamentos 
realizados de forma colaborativa
Resumen
Objetivo: la evaluación económica es un criterio fundamental en 
el posicionamiento de medicamentos. El método MADRE (Mé-
todo de Ayuda para la toma de Decisiones y la Realización de 
Evaluaciones de medicamentos) es ampliamente utilizado en la 
evaluación de medicamentos. Fue desarrollado por el grupo GE-
NESIS de la Sociedad Española de Farmacia Hospitalaria (SEFH), 
e incluye una evaluación económica. Con objeto de mejorar los 
aspectos económicos de este método, analizaremos la experien-
cia previa con esta metodología y propondremos mejoras.
Método: revisión retrospectiva de las evaluaciones económicas 
en los informes de evaluación de medicamentos realizados de 
forma colaborativa (como SEFH) con el método MADRE.
Resultados: se revisaron 32 informes, el 87,5% incluían una 
evaluación económica realizada por los autores y un 65,6% 
una publicada. El 90,6% incluían un análisis de impacto presu-
puestario. 14 informes incluían el coste por año de vida o por 
año de vida ganado ajustado por calidad. 23 informes recibie-
ron alegaciones relacionadas con la evaluación económica. Las 
principales dificultades fueron: baja calidad de la evidencia en 
la población diana, falta de estudios comparativos con el com-
parador relevante, resultados finales no evaluados, falta de 
datos de calidad de vida, precio del medicamento no fijado, in-
certidumbre en la dosis y diferentes precios del medicamento.
Conclusiones: mejoras propuestas: incorporar ayudas para inclu-
sión de costes no farmacológicos, estimación de la supervivencia 
This paper is part of a research project entitled “Guide for economic evaluation and budget impact analysis in drug evaluation reports” which 
receives funding from the Spanish Foundation of Hospital Pharmacy.
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Contribution to scientific literature
GENESIS group of Spanish Society of Hospital Phar-
macy works collaboratively in drug evaluation since 
2005 using its MADRE method. This paper provides a 
review of economic aspects of 32 one-drug evaluation 
reports done collaboratively.
Some improvements can be proposed to facilitate 
drug economic evaluation in MADRE program, e.g. esta-
blishing criteria for drug price selection, decision making 
under uncertainty or cost-effectiveness thresholds in di-
fferent situations.
Introduction
Drug evaluation and selection is one of the key tools 
for establishing drug policy in hospitals. New drugs are 
evaluated by Pharmaceutical and Therapeutic committees 
in order to decide their possible inclusion in the formulary 
and the criteria for their use. This activity has been widely 
developed in Spain1 and in other countries as well2. Since 
the start of this activity, hospital pharmacists have been 
the leaders and they are the main writers of the drug eva-
luation reports used to support the decisions made by the 
Pharmacy and Therapeutics Committees.
Approximately 10 years ago in Spain, there was no 
centralized state initiative for drug selection so a hori-
zontal collaborative system for drug evaluation was ini-
tiated. This system was conducted with the voluntary 
participation of hospital pharmacists throughout Spain. 
The GENESIS group (Grupo de Evaluación de Noveda-
des, Estandarización e Investigación en Selección de 
Medicamentos, meaning group for drug evaluation, 
standardization and research in drug selection) was then 
created within the Spanish Society of Hospital Pharma-
cy (SEFH). The group was made up of pharmacists who 
were widely experienced in drug evaluation.
The GENESIS-SEFH group established a method for 
drug evaluation reports called the MADRE method (Mé-
todo de Ayuda para la toma de Decisiones y la Realiza-
ción de Evaluaciones de medicamentos, meaning me-
thod for assistance in making decisions and writing drug 
evaluation reports)3. The first version was published in 
20054. A study conducted in 2006-2007 showed that 
MADRE was the reference method used in Spanish hos-
ting published economic evaluations; establishing criteria for 
drug price selection, decision-making in conditions of uncertain-
ty and poor quality evidence, dose calculation and cost-effecti-
veness thresholds depending on different situations.
KEYWORDS
Pharmacy service; Hospital; Pharmacy and therapeutics 
committee; Cost effectiveness analysis; Budget Impact analysis; 
Economic evaluation
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y adaptación de evaluaciones económicas publicadas; establecer 
criterios para: selección de precios, toma de decisiones en con-
diciones de incertidumbre o evidencia pobre, cálculo de dosis y 
umbrales de coste-efectividad en diferentes situaciones.
PALABRAS CLAVE
Servicio de farmacia de hospital; Comisión de farmacia y 
terapéutica; Análisis coste-efectividad; Análisis de impacto 
presupuestario; Evaluación económica
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pitals for this purpose5 and in subsequent years, it was 
also adopted by drug evaluation groups from different 
health services and regions 6-11. At the end of 2012, a 
new version of the MADRE program was published 3. 
Aspects such as disease description, data extraction in 
survival analysis, indirect comparisons, therapeutically 
equivalent alternatives and certain aspects of economic 
evaluation and budget impact were improved.
In 2013, a national committee was created for wri-
ting drug therapeutic positioning reports, called IPTs12; 
autonomic representatives and members of the Drug 
Spanish Agency and of the Ministry of Health partici-
pated. IPTs could be a reference or the main reference 
for evaluation committees at different levels13. However, 
up to now, economic evaluation has not been included 
in these IPTs. Therefore, GENESIS reports continue to be 
important documents for drug evaluation committees in 
hospitals, and on health services and autonomic levels.
The main instrument for the diffusion of MADRE and 
drug evaluation reports is the GENESIS-SEFH webpage 
(http://gruposdetrabajo.sefh.es/genesis/). This diffusion 
has contributed to the standardization and quality im-
provement of hospital drug evaluation reports. Howe-
ver, different analyses showed that there was some need 
for improvement5,14; their results helped to improve the 
method in the 2012 version. In one study5 1,805 drug 
evaluation reports conducted in 175 hospitals were re-
viewed. The findings showed different concluding deci-
sions despite the fact that all the reports used the similar 
methodology. It was also observed that different evalua-
tions carried out on the same drug and indication were 
conducted simultaneously, reflecting inefficient repeti-
tion of the same work.
Due to the aforementioned facts, the GENESIS-SEFH 
group decided to work collaboratively on reference drug 
evaluation reports which would be useful for the entire 
country. In 2010, the new collaborative process was ini-
tiated; different reviewers from different hospitals now 
work together on the evaluations. Firstly, an author writes 
the report which is reviewed by a tutor as well as by the 
members of the GENESIS coordinating group. This report 
is made available to the public and emailed to pharma-
ceutical companies and related scientific societies for alle-
gation and comments. The comments are answered by 
the tutor. Both the accepted and rejected comments are 
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included in the final published version of the report. This 
final version also includes the positioning of GENESIS-SE-
FH, the group which represents the scientific society.
As part of this dynamic and continuous improvement 
process, the GENESIS group has now placed great impor-
tance on the economic evaluation aspect. It is a key issue 
when deciding a drug’s place in therapy. Even though eco-
nomic evaluations have undergone improvements throu-
ghout time, the need to include more explanations as well 
as tips and tools for improving the economic content of 
these drug evaluation reports has been recognized. With 
the objective of focusing in on these necessary improve-
ments, we have decided to review and analyze the econo-
mic content of every drug evaluation report already made 
in a collaborative manner so as to identify the principal 
difficulties and to make adequate improvement proposals.
Methods
Every drug evaluation report carried out with the use 
of the GENESIS collaborative method and then published 
on the web page before February 2015 was reviewed.
Reports in which more than one drug was evaluated 
were excluded in order to avoid the difficulty of evaluating 
the report with different conclusions or methods for each 
evaluated drug and to avoid double counting of common 
parts. In addition, the MADRE method was originally desig-
ned to evaluate one drug per report, in spite of the fact that 
it can be used for evaluating various drugs simultaneously. 
In any case, this exclusion was not going to significantly 
alter the results because the multiple drug evaluations were 
only a small percentage of all the reports.
Data were extracted to an Excel page for analysis. Ex-
tracted variables were:
 − Descriptive: drug name, evaluated indication and date 
of publication on the web.
 − Variables related with sections included in the report: 
Whether or not all sections were included and which 
were missing. The MADRE method includes 9 sections: 
1. Drug identification and authors, 2. Applications and 
evaluation process, 3. Descriptive area: medicine and 
health problem, 4. Pharmacological area, 5. Efficacy 
evaluation, 6. Safety assessment, 7. Economic evalua-
tion, 8. Convenience, 9. Conclusions, 10. References. 
Each section includes different subsections.
 − Variables related to the economic evaluation section 
of the evaluation report:
• Whether or not all the MADRE economic evaluation 
sub-sections were included, the ones that were mis-
sing, and the ones that were not considered to be 
applicable to the study. These sub-sections are: 1. Cost 
and incremental costs, 2. Published economic evalua-
tions, 3. Economic evaluation carried out by the author 
of the report (cost-effectiveness analysis), 4. Budget im-
pact at a hospital level, 5. Budget impact at a primary 
care level, 6. Budget impact at a region/country level.
• Whether or not other non-drug costs were included; 
if so, identification of considered costs.
• Whether or not a cost-effectiveness analysis was ca-
rried out by the author; which main effectiveness me-
asure was used; from where it had been obtained; 
and whether or not a subgroup analysis was con-
ducted. The numeric result of the cost-effectiveness 
analysis, its confidence interval and units. In addition, 
whether or not a sensitivity analysis was conducted.
• Whether or not a published cost-effectiveness analy-
sis was reported, who the author was, and what the 
results were.
• Whether or not the economic evaluation was consi-
dered when positioning the drug, and what the po-
sitioning was.
• Whether or not there was a proposed price for the 
new drug based on the economic evaluation. When 
the drug price had not yet been set in Spain, some 
reports included a cost-effective price proposal.
• Whether or not public comments regarding the eco-
nomic evaluation part were received, who made 
them, what aspects did they make reference to, and 
whether or not the comments were accepted.
• Finally, the reviewer collected the main problems 
found in the economic section of the reports because 
they were patent in the report or because they were 
commented on in the report elaboration process.
Results
By February 2015, 36 drug evaluation reports conduc-
ted by hospital pharmacists following the collaborative 
method were available on the GENESIS web page. Four 
were excluded from the analysis because they evaluated 
more than one drug: one evaluated oral anticoagulant 
agents, another bendamustine and rituximab, the third 
one evaluated bosutinib and ponatinib, and the fourth 
one evaluated ipilimumab and vemurafenib. Therefore, 
32 drug evaluation reports were included in the analysis. 
Of these, four were in a draft phase; therefore, public 
comments had not been included yet. In four reports, 
off-label indications were evaluated.
The drugs and indications evaluated are shown in Ta-
ble 1. Three reports were published in 2015, eleven in 
2014, three in 2013, eight in 2012, four in 2011, and 
three in 2010. All parts of the MADRE method were in-
cluded in each report.
With reference to economic evaluation sections:
 − Drug costs and incremental costs vs. comparator were 
included in each report.
 − An economic evaluation was conducted by the au-
thors in 87.5% of the reports; theses were cost-effec-
tiveness analyses in 24 cases and cost-minimization 
analyses in 4 cases. Of the four remaining reports, 
two failed to include a section dedicated to economic 
evaluation, while the third case included a comment 
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saying that said type of evaluation was not applica-
ble, and the fourth report included a budget impact 
analysis.
 − In 65.6% of the evaluations, a published economic 
evaluation was available and commented on in the 
report. In all but two of the reports, the published 
economic evaluation section was included (either in-
cluding information from the publication or indicating 
that a search had been conducted but no published 
economic evaluation had been found).
 − In 90.6% of the reports, some type of budget impact 
was included. Hospital impact was included in 43.7% 
of the cases, primary care impact in 6.2%, and natio-
nal impact in 71.9% of the cases.
With regard to costs, the drug costs were always in-
cluded. Non-drug costs were only included on five occa-
sions. In one case, these costs corresponded to surgery, 
arthroscopy and rehabilitation; other cases involved In-
ternational Normalized Ratio (INR) test, febrile neutro-
penia, adverse effects and intravenous administration 
of drugs, and day care hospitalization. In other reports, 
some costs were identified but not quantified. In one 
additional report, a sensitivity analysis was conducted, 
including failure and hospitalization costs.
In relation to the cost-effectiveness analysis conduc-
ted by the author of the drug evaluation report, this was 
included in 24 reports, accounting for 75% of the eva-
luated drugs. Three reports did not include this section; 
Table 1. Evaluated drugs and indications
Drug Indication
Abiraterone Naïve castration resistant metastatic prostate cancer
Adalimumab Juvenile Idiopathic Arthritis (JIA), uveitis associated to JIA (OL)
Aflibercept Metastatic colorectal cancer
Bedaquiline Multi-resistant pulmonary tuberculosis 
Belatacept Prophylaxis in kidney transplant
Bevacizumab Age related macular degeneration (OL)
Brentuximab Relapsing CD30+ Hodgkin Lymphoma and anaplastic large-cell lymphoma 
Cabazitaxel Metastatic prostate cancer
Ceftaroline Community acquired pneumonia, skin and soft tissue infection
Autologous human chondrocytes Repair of cartilage defects of the knee 
Crizotinib Non-small cell lung cancer 
Dabigatran Atrial fibrillation 
Eribulin Locally advanced or metastatic breast cancer 
Everolimus Pediatric sub-ependymal Giant Cell Astrocytoma
Fidaxomicin Clostridium difficile infection
Fingolimod Remittent recurrent multiple sclerosis 
Ipilimumab First line of unresectable or metastatic melanoma 
Ivacaftor Cystic fibrosis in patients > 6 years old and with G551D mutation in gen CFTR
Nab-paclitaxel Pancreatic cancer
Pazopanib Advanced renal cell cancer
Pertuzumab Unresectable locally recurrent or metastatic breast cancer 
Plerixafor Hematopoietic stem-cell mobilization in patients < 18 years old (OL) 
Prasugrel Antithrombotic prophylaxis in Acute Coronary Syndrome (ACS) with percutaneous intervention 
Raltegravir HIV in naïve adults 
Regorafenib Gastrointestinal stromal tumor 
Romiplostim Idiopathic thrombocytopenic purpura in patients <18 years old (OL) 
Sofosbuvir Hepatitis C
Sunitinib Neuroendocrine pancreatic tumor 
Ticagrelor ACS
Tolvaptan Inadequate secretion of antidiuretic hormone 
Trastuzumab emtansine Locally advanced or metastatic her2+ breast cancer 
Vedolizumab Crohn’s disease
OL = Off-label.
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one included a budget impact analysis in this section, 
and in 4 reports (15.6%), since no difference was found 
between treatments with regard to health effects, a cost 
minimization analysis was conducted. In Table  2, the 
effectiveness units used are shown. Health results were 
obtained from clinical trials except on two occasions. On 
one occasion, QALYs were obtained from another study, 
and in the other case, they were obtained from clinical 
trials with some assumptions.
Subgroup analysis was performed in 9 (28.1%) eva-
luations.
With regard to the mean cost-effectiveness ratio, in 
the 14 reports that calculated the cost per life year gai-
ned or per quality adjusted life year gained, this ratio 
was 108,088€. This ratio was less than 30,000 € on just 
one occasion; in five drugs, the ratio was approxima-
tely 50,000-60,000€, in one case between 70,000 and 
80,000, and in 7 cases, it was more than 100,000€.
A sensitivity analysis was conducted in every report 
that included a cost-effectiveness analysis except in two 
cases. However, most of the time the analysis was not 
identified as a sensitivity analysis and it was a one-way 
sensitivity analysis. Variables analyzed in sensitivity analy-
ses are listed in Table 3.
National Budget impact was present in 24 reports. 
Its methodology and uncertainty estimation differed be-
tween reports. Mean national impact was approxima-
tely 71 million euros with a wide range of variability; 
the median value was 24 million euros; minimum being 
0.1 and maximum being 1,129 million euros. Thirteen 
reports also included national health impact, with health 
variables being very diverse; the life years gained were 
only estimated on 3 occasions.
Twenty-one evaluations included a published eco-
nomic evaluation. This was carried out by the Natio-
nal Institute for Health and Care Excellence (NICE) on 
nine occasions, by the Scottish Medicines Consortium 
in 6 cases, by the Canadian Agency for Drugs and Te-
chnologies in Health (CADTH) in two reports, and one 
was made by the Australian Medical Services Advisory 
Committee (MSAC) while one was made by the World 
Health Organization (WHO); the rest were papers pu-
blished by other professionals. Seventeen reports inclu-
ded cost-effectiveness analysis, with cost per QALY as 
the main result.
Twenty-three reports received public comments re-
garding the economic section, 22 of which were made 
by pharmaceutical companies. The comments made re-
Table 2. Effectiveness units used in cost-effectiveness analyses conducted by the authors of drug evaluation reports
Effectiveness unit Number of reports Percentage of the 32 reports
Percentage of patients with clinical event* 11 34.4
Median overall survival 8 25
Median progression free survival 3 9.4
Quality adjusted life year (QALY) 2** 6.2
*Clinical event varies between reports, it can be: patients with a specific reduction in tumor size, with normal natremia at 30 days, with recu-
rrence, cured, with response, without stroke, with remission, alive, with adequate cell count.
**In 4 additional reports cost/QALY was calculated but it was not identified as the main analysis.
Table 3. Variables used in sensitivity analysis (the effect of multiple variables could be evaluated in one report)
Variable
Number of reports that include each 
variable in the sensitivity analysis
Confidence interval of the main clinical trial result 12
Data obtained from a different source 1
Quality adjusted life years (QALYs) 4
Overall survival at a certain point in time 4
Different treatment durations 2
Different costs 2
Other outcome variables (patient cured, non-neutropenic, with non-fatal 
myocardial infarction, with sustained viral response at 12 weeks, etc.) 
5
Including other costs 1
Another comparator 2
Other utility values 2
Other scenarios 1
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ference to costs and incremental costs in 17 evaluations, 
another 17 referred to cost-effectiveness analysis con-
ducted by the author; on four occasions the comments 
were related to hospital budget impact, one was con-
cerning budget impact in primary care and 10 regarding 
national budget impact. One drug evaluation report 
could have several comments regarding different sec-
tions. Main comments are included in Table 4. In three 
Table 4. Comments on the economic section received during the public allegation period
Content Number of reports
Effectiveness measures 
Just clinical trial results are analyzed 1
Conduct ICER with other variables different from the main variable 1
Use the difference in median overall survival even if it is not statistically significant 1
Use mean survival data instead of median 2
Not to make assumptions in utility values 1
Comparator
Use a different comparator 1
Do not use indirect comparisons 1
Costs
Use a different treatment duration 5
Use just official drug costs (referenced in BOTPlus 2.0) 1
Do not use a drug price that is not yet approved 1
Do not consider left-over vials 1
Consider left-over vials 1
Apply drug discounts according to Spanish legislation 2
Include other costs 5
Use PVL instead of PVP 2
Do not use foreign drug costs 1
Establish which patient weight has to be considered when calculating doses 1
Use PVL, not real hospital acquisition cost 1
Do not use DDD if not set by WHO, use doses in OL 1




Accept variability in dosing calculation 1
Cost-effectiveness
Do not use EoL criteria 1
Do not use non-definitive NICE results 1
Include one published economic evaluation 2
Do not use NICE criteria 1
Do not calculate cost per NNT 3
Include reports from other evaluating bodies (universities, associations, companies) 1
Budget impact
Use a different population in BI 4
Use a different alternative in BI 2
Consider a partial introduction of the new drug in the BI 2
Cost for primary care drugs must not be the total drug cost as there is co-payment by the patient 1
BI = Budget impact, BOT= Spanish drug database that includes official drug prices; DDD = Defined daily dose, EoL = “End of life” criteria; ICER 
= Incremental cost-effectiveness ratio; NICE = National Institute for Health and Care Excellence; NNT = Number needed to treat; OL= Off-label 
use, PVL = Company selling price, PVP= Public selling price, OS = Overall survival WHO = World Health Organization.
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reports, no comments were accepted by the authors; in 
13 reports, some comments were accepted and in 7 eva-
luations, every comment was accepted and included in 
the report.
In every report, except for three evaluations, economic 
aspects were clearly considered when deciding a drug’s 
place in therapy. In 8 reports, a drug cost was proposed.
At the end of the evaluation, a proposal was included 
in 31 of the 32 reports. In 5 cases, the recommendation 
was to not include the drug in the hospital formulary; 
in four cases the evaluated drug was considered to be a 
therapeutically equivalent alternative; in one case it was 
considered as an alternative treatment without conside-
ring it as being therapeutically equivalent, and in 19 re-
ports the recommendation was to include the drug with 
specific criteria for its use. On two occasions the decision 
was postponed until more data were available.
Problems in economic sections identified by the re-
viewer are listed in Table 5.





Lack of comparative studies vs. the preferred alternative, and indirect comparison is not possible 6
Lack of comparative studies vs. the preferred alternative, and indirect comparison is not statistically significant 2
Lack of comparison with active alternatives 7
Health outcome issues 
Final outcome results not available 5
No long-term overall survival data 11
Insufficient efficacy evidence, benefit-risk balance unknown 3
No subgroup evidence 3
Deficiencies in clinical trials 1
No overall survival results 6
No utility values 4
Various outcome variables, differences in the main variable are not statistically significant; however, there are 
differences in other variables. 
3
No long-term safety data 3
Evidence from non-inferiority studies 1
Combined main outcome variable 1
Target population different from that included in trials 1
No definitive evidence in target subgroup 1
Costs
No drug price available 10
Drug dose or duration not clearly defined 6
Important costs are missing 1
Reimbursed vs. official price 1
Cost-effectiveness
Calculate ICER when adding one drug to standard treatment 1
No published economic evaluations available 3
ICER = Incremental cost-effectiveness ratio.
Discussion
Drug evaluation reports are now more comprehensi-
ve than those published before 2010. Before this date, 
some sections were not included and the content was 
quite simple14.
When drugs are evaluated, no published economic 
evaluation is available in approximately 35% of the ca-
ses. It is necessary to conduct an economic evaluation, 
not only because it is absent, but also because it is fre-
quently difficult to adapt a published economic evalua-
tion due to problems in evaluating its quality and the 
lack of access to some data. In this study, an economic 
evaluation was conducted by the authors in 87% of the 
reports, a higher percentage than in drug evaluations 
conducted between 2004 and 200714. A similar trend 
was observed with the budget impact analysis.
The main difficulties faced when conducting econo-
mic evaluations in these reports include the lack of: qua-
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9. To propose methodology for drug evaluations with 
poor or nonexistent evidence.
10. To establish procedures when final variables, such 
as survival, cannot be estimated.
11. To set criteria for dosing calculations according to 
weight, body surface area, etc. as well as the dura-
tion of therapy.
12. To establish recommendations for efficiency criteria 
in specific situations, such as orphan drugs, end of 
life, etc.
13. To give recommendations regarding a gradual intro-
duction of the new drug when calculating budget 
impact.
14. To establish criteria for subgroup analysis.
15. To propose a cost-effectiveness threshold, even if it 
is not official, in order to base all the recommenda-
tions on the same criterion.
16. To explicitly show criteria for decision making.
In conclusion, reviewing the economic sections of the 
drug evaluation reports conducted by Spanish hospital 
pharmacists in a collaborative manner has helped to 
identify the main difficulties that arise when conducting 
this part of the reports. This review has also led to the 
proposal of at least 16 improvements for facilitating and 
increasing the quality of the economic evaluation sec-
tion in the drug evaluation reports.
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lity data in target population, comparative evidence with 
alternative drugs being used in clinical practice, long 
term results, quality of life data, drug price, and clear 
dosing strategy. Another difficulty concerns the availabi-
lity of various drug prices
The lack of a drug price was partially managed in the 
new MADRE version, including recommendations for 
maximum drug price proposal calculation so as to make 
a drug cost-effective. This method is based on the esti-
mation of the incremental QALYs obtained with one drug 
vs. an alternative one, and multiplying it by the threshold 
willingness to pay per QALY gained most frequently used 
in Spain, although it is not an official number.
The quality of the economic sections has increased; 
however, there is still room for more improvement. The 
following important ideas should be kept in mind:
1. To include other costs in addition to the drug costs. 
To make it easier, a table with the most frequently 
used costs can be included in the MADRE program. 
For example, in oncology, the cost of one hospitaliza-
tion day, one hour cost in day care, cost of a neutro-
penic episode, of a neutropenic infection, and so on. 
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permits comparisons between different pathologies 
and decreases subjectivity in cost-effectiveness clas-
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3. To include helpful tips for performing sensitivity 
analysis and for interpreting it, as well as tips for 
incorporating this uncertainty in the decision-ma-
king process. It could be interesting to give some 
examples of variables frequently tested in sensitivity 
analyses.
4. To include instructions regarding how to transfer 
QALY published data to our context.
5. To identify the main analysis from the analyses con-
ducted as part of the sensitivity analysis in every re-
port.
6. To fix criteria when it is possible to conduct a 
cost-minimization analysis instead of a cost-effec-
tiveness analysis, considering statistical and clinical 
differences between treatments.
7. To establish criteria for selecting prices for calcu-
lations (official price for the hospital, price for the 
patient, reimbursed price, real hospital acquisition 
price, price as a foreign drug, etc.), if different cri-
teria are necessary for ambulatory care drugs and 
hospital drugs, consideration of vial left-overs, etc. 
Uniformity in calculations is necessary for fair bud-
get distribution.
8. To give recommendations regarding how to handle 
the lack of comparative studies when indirect com-
parisons are not possible.
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